NASDAQ:INDV Indivior Q1 2026 Earnings Report $35.38 -0.47 (-1.31%) Closing price 04:00 PM EasternExtended Trading$35.57 +0.19 (+0.55%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Indivior EPS ResultsActual EPS$0.96Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIndivior Revenue ResultsActual Revenue$317.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIndivior Announcement DetailsQuarterQ1 2026Date3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsIndivior's Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesEarnings HistoryCompany Profile Indivior Earnings HeadlinesComparing Contineum Therapeutics (NASDAQ:CTNM) and Indivior (NASDAQ:INDV)September 30 at 4:58 AM | americanbankingnews.comHead-To-Head Analysis: Indivior (NASDAQ:INDV) and Addex Therapeutics (NASDAQ:ADXN)September 28 at 5:45 AM | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 1 at 1:00 AM | Stansberry Research (Ad)Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNSeptember 24, 2026 | businesswire.comIndivior (INDV) Receives a Rating Update from a Top AnalystSeptember 20, 2026 | theglobeandmail.comIndivior (INDV) Receives a Rating Update from a Top AnalystSeptember 20, 2026 | theglobeandmail.comSee More Indivior Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indivior? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indivior and other key companies, straight to your email. Email Address About IndiviorIndivior (NASDAQ:INDV) (NASDAQ: INDV) is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company’s primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery. Indivior’s portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia. The company also markets Opvee, a nalmefene nasal spray intended for the emergency treatment of opioid overdose in adults and pediatric patients. The company was established as an independent business in 2014 following its separation from Reckitt Benckiser. Indivior is headquartered in Richmond, Virginia, and serves patients and healthcare providers primarily in the United States, as well as in selected international markets. Its products are distributed through healthcare providers, pharmacies and other treatment channels. Indivior is led by Chief Executive Officer Mark Crossley. The company continues to focus its research, development and commercial activities on expanding access to treatments for opioid use disorder and addressing other conditions associated with addiction and mental health.View Indivior ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
